Mylan Wins Generic Prilosec(R) Patent Litigation

Wednesday, June 11, 2008 General News J E 4
PITTSBURGH, June 10 Mylan Inc. (NYSE: MYL)announced today that the U.S. Court of Appeals for the Federal Circuit hasaffirmed a May 2007 District Court ruling stating that Mylan's 10 mg and 20 mgOmeprazole delayed-release capsules do not infringe patents asserted againstMylan by AstraZeneca. Omeprazole is the generic version of AstraZeneca LP'sPrilosec(R).

Mylan launched its Omeprazole products on August 4, 2003, despite thepatent infringement litigation, which at the time was unprecedented in thegeneric pharmaceutical industry.

"Once again, we are pleased to have prevailed in court, and we believethat this decision ends the patent litigation surrounding this product for ourcompany," said Mylan Vice Chairman and CEO Robert J. Coury. "Our originaldecision to launch this product means that consumers, the government andthird-party payors have benefited significantly for nearly five years becausethey've had access to a lower-cost generic version of Prilosec."

Mylan Inc., with a presence in more than 90 countries, ranks among theleading diversified generic and specialty pharmaceutical companies in theworld. The company maintains one of the industry's broadest -- and highestquality -- product portfolios, supported by a robust product pipeline; owns acontrolling interest in the world's second largest active pharmaceuticalingredient manufacturer; and operates a specialty business focused onrespiratory and allergy therapies.

SOURCE Mylan Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
AUDIO from Medialink and Pfizer: Free Programs for...
30th Street Senior Center and Posit Science Put Th...